Uncategorized
portfolio of drugs
Table of Contents
NU670 Psychopharmacology and Health promotion
Neurotransmitter Chart (Unit 2)
Antipsychotics Chart (Unit 7)
Antidepressants, Anxiolytics, & Mood Stabilizers Chart (Units 5, 6)
Substance Use Resources (Chart links) (Units 11, 13, 14)
Additional Resources List
| Neurotransmitters Chart | |||||||
| Function (Excitatory or Inhibitory) | Locations | Receptors | Effects of Deficient | Effects of Surplus | Agonist Drug | Antagonist Drug | |
| Acetylcholine |
|
||||||
| Dopamine |
|
||||||
| Endorphins |
|
||||||
| GABA |
|
||||||
| Glutamate |
|
||||||
| Glycine |
|
||||||
| Glutamate |
|
||||||
| Norepinephrine |
|
||||||
| Serotonin |
|
||||||
Notes:
| Antipsychotics | ||||||||||||||
| First Generation | Side Effects (L=Low, M=Moderate, H=High) | |||||||||||||
| Generic Name | Trade Name | Route(s) of Administration | LAI option | Starting Dose | Half Life | Indications (s/sx & diagnosis) | MOA (neurotransmitter effects) | EPS | Hyperlipidemia | T2DM | Weight Gain | Cognitive Issue | Other SE | Costs |
| Second Generation | ||||||||||||||
Notes:
| Antidepressants, Anxiolytics & Mood Stabilizers | ||||||||||||||
| Antidepressants | Side Effects (L=Low, M=Moderate, H=High) | |||||||||||||
| Generic Name | Trade Name | Route(s) of Administration | LAI option | Starting Dose | Half Life | Indications (s/sx & diagnosis) | MOA (neurotransmitter effects) | EPS | Hyperlipidemia | T2DM | Weight Gain | Cognitive Issue | Other SE | Costs |
| SSRIs | ||||||||||||||
| SNRIs | ||||||||||||||
| TCAs | ||||||||||||||
| MAOIs | ||||||||||||||
| Atypical | ||||||||||||||
| Anxiolytics | ||||||||||||||
| Benzodiazepines | ||||||||||||||
| Barbiturates | ||||||||||||||
| Mood Stabilizers | ||||||||||||||